SLC16A10

Summary

SLC16A10 (solute carrier family 16 member 10, HGNC:17027) is a protein-coding gene on chromosome 6q21, encoding Monocarboxylate transporter 10 (Q8TF71). Sodium- and proton-independent thyroid hormones and aromatic acids transporter.

SLC16A10 is a member of a family of plasma membrane amino acid transporters that mediate the Na(+)-independent transport of aromatic amino acids across the plasma membrane.

Source: NCBI Gene 117247 — RefSeq curated summary.

At a glance

• GWAS associations: 18
• Clinical variants (ClinVar): 68 total
• MANE Select transcript: NM_018593

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17027
Approved symbol	SLC16A10
Name	solute carrier family 16 member 10
Location	6q21
Locus type	gene with protein product
Status	Approved
Aliases	TAT1, MCT10
Ensembl gene	ENSG00000112394
Ensembl biotype	protein_coding
OMIM	607550
Entrez	117247

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000368850, ENST00000368851, ENST00000419619, ENST00000439288, ENST00000465319, ENST00000888692

RefSeq mRNA: 1 — MANE Select: NM_018593 NM_018593

CCDS: CCDS5089

Canonical transcript exons

ENST00000368851 — 6 exons

Exon	Start	End
ENSE00000762036	111218814	111219042
ENSE00003323161	111222003	111231194
ENSE00003617357	111172695	111172839
ENSE00003618898	111177212	111177665
ENSE00003730926	111087503	111088095
ENSE00003756754	111206592	111206735

Expression profiles

Bgee: expression breadth ubiquitous, 201 present calls, max score 89.69.

FANTOM5 (CAGE): breadth broad, TPM avg 2.5658 / max 148.4644, expressed in 713 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
69272	2.1104	624
69271	0.4554	290

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gastrocnemius	UBERON:0001388	89.69	gold quality
muscle of leg	UBERON:0001383	88.05	gold quality
secondary oocyte	CL:0000655	87.93	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.64	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	87.47	gold quality
buccal mucosa cell	CL:0002336	87.42	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	87.14	gold quality
biceps brachii	UBERON:0001507	86.73	gold quality
muscle organ	UBERON:0001630	86.71	gold quality
duodenum	UBERON:0002114	86.19	gold quality
vastus lateralis	UBERON:0001379	86.12	gold quality
jejunal mucosa	UBERON:0000399	85.97	gold quality
mammalian vulva	UBERON:0000997	85.27	gold quality
body of pancreas	UBERON:0001150	85.18	gold quality
hindlimb stylopod muscle	UBERON:0004252	85.06	gold quality
quadriceps femoris	UBERON:0001377	84.70	silver quality
choroid plexus epithelium	UBERON:0003911	82.40	gold quality
upper leg skin	UBERON:0004262	82.34	gold quality
skeletal muscle tissue	UBERON:0001134	81.66	gold quality
deltoid	UBERON:0001476	81.16	silver quality
pancreas	UBERON:0001264	80.09	gold quality
penis	UBERON:0000989	79.71	gold quality
oocyte	CL:0000023	79.31	gold quality
amniotic fluid	UBERON:0000173	78.90	gold quality
placenta	UBERON:0001987	77.85	gold quality
jejunum	UBERON:0002115	77.63	gold quality
skin of leg	UBERON:0001511	77.60	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.37	gold quality
skin of hip	UBERON:0001554	77.17	gold quality
muscle tissue	UBERON:0002385	76.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	15.49

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

94 targeting SLC16A10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-302A-3P	99.89	71.23	1777

Literature-anchored findings (GeneRIF, showing 13)

• MCT10 is at least as active a thyroid hormone transporter as hMCT8, and that both transporters facilitate iodothyronine uptake as well as efflux. (PMID:18337592)
• Increased MCT8 and decreased MCT10 expression within placentae of pregnancies complicated by IUGR may contribute to aberrant development of the fetoplacental unit. (PMID:20167367)
• monocarboxylate transporter 10 facilitates bromoacetyl [(125)I] iodothyronine transport, but is not labeled by it (PMID:21315799)
• Compared with the adult cerebral cortex, mRNAs encoding OATP1A2, OATP1C1, OATP3A1 variant 2, OATP4A1, LAT2 and CD98 were reduced in fetal cortex at different gestational ages, whilst mRNAs encoding MCT8, MCT10, OATP3A1 variant 1 and LAT1 were similar. (PMID:21486766)
• The strong expression of MCT10 and OATP1C1 in the human hypothalamus indicates a possible role in the regulation of the hypothalamus-pituitary-thyroid axis. (PMID:21508134)
• High TAT1 expression is associated with metastasis and recurrence in endometrial cancer. (PMID:26779635)
• the aim of this study was to examine if MCT8 and MCT10 increase the availability of triiodothyronine for its nuclear receptor. (PMID:27492966)
• In the MCT10 modeled structure, N81 appeared to protrude into the putative trajectory of tryptophan. (PMID:28754537)
• Molecular predictor of TaT1 patients. (PMID:31595333)
• Single Nucleotide Polymorphisms in Thyroid Hormone Transporter Genes MCT8, MCT10 and Deiodinase DIO2 Contribute to Inter-Individual Variance of Executive Functions and Personality Traits. (PMID:31820424)
• Association of DIO2 and MCT10 Polymorphisms With Persistent Symptoms in LT4-Treated Patients in the UK Biobank. (PMID:37740545)
• MiR-21-5p modulates LPS-induced acute injury in alveolar epithelial cells by targeting SLC16A10. (PMID:38750066)
• The circular RNA circSLC16A10 alleviates diabetic retinopathy by improving mitochondrial function via the miR-761-5p/MFN2 axis. (PMID:38960059)

Cross-species orthologs

17 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc16a10	ENSDARG00000020984
mus_musculus	Slc16a10	ENSMUSG00000019838
rattus_norvegicus	Slc16a10	ENSRNOG00000000588
drosophila_melanogaster	Mct1	FBGN0023549
drosophila_melanogaster	CG14196	FBGN0031002
drosophila_melanogaster	CG8051	FBGN0031012
drosophila_melanogaster	Sln	FBGN0033657
drosophila_melanogaster	CG8468	FBGN0033913
drosophila_melanogaster	Targ	FBGN0033955
drosophila_melanogaster	CG13907	FBGN0035173
drosophila_melanogaster	out	FBGN0259834
caenorhabditis_elegans		WBGENE00003986
caenorhabditis_elegans		WBGENE00010834
caenorhabditis_elegans		WBGENE00015273
caenorhabditis_elegans		WBGENE00015676
caenorhabditis_elegans		WBGENE00020168
caenorhabditis_elegans		WBGENE00021227

Paralogs (13): SLC16A8 (ENSG00000100156), SLC16A6 (ENSG00000108932), SLC16A7 (ENSG00000118596), SLC16A3 (ENSG00000141526), SLC16A2 (ENSG00000147100), SLC16A12 (ENSG00000152779), SLC16A1 (ENSG00000155380), SLC16A14 (ENSG00000163053), SLC16A9 (ENSG00000165449), SLC16A4 (ENSG00000168679), SLC16A5 (ENSG00000170190), SLC16A11 (ENSG00000174326), SLC16A13 (ENSG00000174327)

Protein

Protein identifiers

Monocarboxylate transporter 10 — Q8TF71 (reviewed: Q8TF71)

Alternative names: Aromatic amino acid transporter 1, Solute carrier family 16 member 10, T-type amino acid transporter 1

All UniProt accessions (4): Q8TF71, H0Y3W8, H0Y5M8, Q9P1I2

UniProt curated annotations — full annotation on UniProt →

Function. Sodium- and proton-independent thyroid hormones and aromatic acids transporter. Mediates both uptake and efflux of 3,5,3’-triiodothyronine (T3) and 3,5,3’,5’-tetraiodothyronine (T4) with high affinity, suggesting a role in the homeostasis of thyroid hormone levels. Responsible for low affinity bidirectional transport of the aromatic amino acids, such as phenylalanine, tyrosine, tryptophan and L-3,4-dihydroxyphenylalanine (L-dopa). Plays an important role in homeostasis of aromatic amino acids.

Subcellular location. Cell membrane. Basolateral cell membrane.

Tissue specificity. Strongly expressed in kidney and skeletal muscle and at lower level in placenta and heart.

Post-translational modifications. Not N-glycosylated.

Similarity. Belongs to the major facilitator superfamily. Monocarboxylate porter (TC 2.A.1.13) family.

RefSeq proteins (1): NP_061063* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011701	MFS	Family
IPR020846	MFS_dom	Domain
IPR036259	MFS_trans_sf	Homologous_superfamily
IPR050327	Proton-linked_MCT	Family

Pfam: PF07690

Catalyzed reactions (Rhea), 5 shown:

• L-phenylalanine(in) = L-phenylalanine(out) (RHEA:27950)
• L-tyrosine(in) = L-tyrosine(out) (RHEA:68572)
• L-tryptophan(in) = L-tryptophan(out) (RHEA:70947)
• 3,3’,5-triiodo-L-thyronine(out) = 3,3’,5-triiodo-L-thyronine(in) (RHEA:71811)
• L-thyroxine(out) = L-thyroxine(in) (RHEA:71819)

UniProt features (40 total): topological domain 13, transmembrane region 12, modified residue 5, sequence conflict 4, compositionally biased region 2, chain 1, region of interest 1, sequence variant 1, mutagenesis site 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
9HHQ	ELECTRON MICROSCOPY	3.5
9GSZ	ELECTRON MICROSCOPY	3.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TF71-F1	82.57	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 263, 498, 501, 503, 504

Mutagenesis-validated functional residues (1):

Position	Phenotype
81	does not affect subcellular localization. abolishes tryptophan import activity.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-352230	Amino acid transport across the plasma membrane
R-HSA-382551	Transport of small molecules
R-HSA-425393
R-HSA-425407	SLC-mediated transmembrane transport

MSigDB gene sets: 228 (showing top): GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, PAX4_01, ATACCTC_MIR202, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_HORMONE_TRANSPORT, GOBP_THYROID_HORMONE_METABOLIC_PROCESS, GOBP_AMINO_ACID_TRANSMEMBRANE_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_ORGANIC_ACID_TRANSPORT, MODULE_206, GOBP_AMINO_ACID_TRANSPORT, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_SECRETION, GOBP_SIGNAL_RELEASE, CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN

GO Biological Process (11): thyroid hormone generation (GO:0006590), amino acid transport (GO:0006865), aromatic amino acid transport (GO:0015801), thyroid hormone transport (GO:0070327), thyroid-stimulating hormone secretion (GO:0070460), amino acid transmembrane transport (GO:0003333), phenylalanine transport (GO:0015823), tryptophan transport (GO:0015827), tyrosine transport (GO:0015828), transmembrane transport (GO:0055085), carboxylic acid transmembrane transport (GO:1905039)

GO Molecular Function (9): L-tyrosine transmembrane transporter activity (GO:0005302), amino acid transmembrane transporter activity (GO:0015171), aromatic amino acid transmembrane transporter activity (GO:0015173), L-phenylalanine transmembrane transporter activity (GO:0015192), L-tryptophan transmembrane transporter activity (GO:0015196), thyroid hormone transmembrane transporter activity (GO:0015349), transmembrane transporter activity (GO:0022857), protein binding (GO:0005515), carboxylic acid transmembrane transporter activity (GO:0046943)

GO Cellular Component (4): plasma membrane (GO:0005886), basolateral plasma membrane (GO:0016323), cell junction (GO:0030054), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
SLC-mediated transport of amino acids	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
carboxylic acid transport	3
transmembrane transport	3
aromatic amino acid transport	3
aromatic amino acid transmembrane transporter activity	3
L-amino acid transmembrane transporter activity	3
transport	2
nitrogen compound transport	2
amino acid transport	2
transmembrane transporter activity	2
cellular anatomical structure	2
thyroid hormone metabolic process	1
hormone transport	1
peptide hormone secretion	1
L-amino acid transport	1
cellular process	1
tyrosine transport	1
amino acid transmembrane transport	1
carboxylic acid transmembrane transporter activity	1
phenylalanine transport	1
tryptophan transport	1
secondary active transmembrane transporter activity	1
thyroid hormone transport	1
transporter activity	1
binding	1
carboxylic acid transmembrane transport	1
membrane	1
cell periphery	1
basal plasma membrane	1
plasma membrane region	1

Protein interactions and networks

STRING

728 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC16A10	SLCO1C1	Q9NYB5	825
SLC16A10	SLC7A8	Q9UHI5	695
SLC16A10	DIO2	Q92813	641
SLC16A10	SLCO4A1	Q96BD0	601
SLC16A10	SLC7A5	Q01650	579
SLC16A10	SLCO1A2	P46721	574
SLC16A10	SLC43A2	Q8N370	556
SLC16A10	SLC7A6	Q92536	545
SLC16A10	THRB	P10828	532
SLC16A10	MCTS1	Q9ULC4	522
SLC16A10	THRA	P10827	514
SLC16A10	SLC7A9	P82251	511
SLC16A10	CRYM	Q14894	510
SLC16A10	SLC3A2	P08195	500
SLC16A10	SLC6A14	Q9UN76	495

IntAct

42 interactions, top by confidence:

A	B	Type	Score
LRRC32	SMPD2	psi-mi:“MI:0914”(association)	0.640
SLC16A10	TMEM14B	psi-mi:“MI:0915”(physical association)	0.560
SLC16A10	INSIG2	psi-mi:“MI:0915”(physical association)	0.560
SLC16A10	FUNDC2	psi-mi:“MI:0915”(physical association)	0.560
TOR1AIP2	TMEM223	psi-mi:“MI:0914”(association)	0.530
CNDP1	POTEF	psi-mi:“MI:0914”(association)	0.530
SLC22A9	GPR89A	psi-mi:“MI:0914”(association)	0.530
ARMC6	SLC27A2	psi-mi:“MI:0914”(association)	0.530
DHRS9	MFSD4B	psi-mi:“MI:0914”(association)	0.530
SLC16A10	LAS1L	psi-mi:“MI:0915”(physical association)	0.400
UPK1A	TMEM223	psi-mi:“MI:0914”(association)	0.350
TMPRSS11B		psi-mi:“MI:0914”(association)	0.350
EDEM2	HACD1	psi-mi:“MI:0914”(association)	0.350
SLC22A9	GPR89A	psi-mi:“MI:0914”(association)	0.350
ARMC6	SLC27A2	psi-mi:“MI:0914”(association)	0.350
KLK8	MT-ND1	psi-mi:“MI:0914”(association)	0.350
GYG2	GYS1	psi-mi:“MI:0914”(association)	0.350
DHRS9	ATP2B2	psi-mi:“MI:0914”(association)	0.350
ERAP1	TMEM87A	psi-mi:“MI:0914”(association)	0.350
CRELD1	TMEM223	psi-mi:“MI:0914”(association)	0.350
LRRC55	TMEM120B	psi-mi:“MI:0914”(association)	0.350
MGARP	RTL8C	psi-mi:“MI:0914”(association)	0.350
SLC3A2	GET1	psi-mi:“MI:0914”(association)	0.350
TMPRSS11B	ADAM10	psi-mi:“MI:0914”(association)	0.350
KLK1	SLC25A20	psi-mi:“MI:0914”(association)	0.350
UPK2	NRP2	psi-mi:“MI:0914”(association)	0.350
LYZL6	PLXNA2	psi-mi:“MI:0914”(association)	0.350

BioGRID (153): SLC16A10 (Synthetic Growth Defect), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), SLC16A10 (Affinity Capture-MS), INSIG2 (Two-hybrid)

ESM2 similar proteins: A1L1W9, A1L272, A2SWM2, A8WGF7, D3Z5L6, D4A9K4, F4IKF6, G5E8K6, G8XYX6, O15374, O35440, O70324, O70451, O70594, P30638, P36021, P53985, P53986, P53987, P53988, P57057, P58355, Q00910, Q03064, Q0VA82, Q3MHW6, Q3U9N9, Q569T7, Q5M7K3, Q5U3U7, Q5XGK0, Q63344, Q640L2, Q6DCX5, Q6GPQ3, Q6NMN6, Q6NT16, Q6NUB3, Q7ZWG6, Q8AVC3

Diamond homologs: A1L1W9, G8XYX6, O15374, O70324, P36021, Q3U9N9, Q7RTX9, Q8K1P8, Q8R0M8, Q8TF71, Q91Y77, M0RCI4, P36032, Q7TM99, Q5R5M4, Q7RTY1, Q8K1C7, Q5ZJU0, B0XWL0, B8N0F1, G5E8K6, O15375, O35440, O70451, P53988, P57787, Q17QR6, Q63344, Q66HE2, Q7RTY0, Q8CE94, S0ECK8, A0LNN5, O35308, Q6P2X9, Q6ZSM3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

68 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	52
Likely benign	7
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

2529 predictions. Top by Δscore:

Variant	Effect	Δscore
6:111088091:GACAG:G	donor_gain	1.0000
6:111137678:G:GT	donor_gain	1.0000
6:111172693:A:AG	acceptor_gain	1.0000
6:111172694:G:GG	acceptor_gain	1.0000
6:111172837:AAGG:A	donor_loss	1.0000
6:111172840:G:GC	donor_loss	1.0000
6:111172841:T:G	donor_loss	1.0000
6:111206586:CTATA:C	acceptor_loss	1.0000
6:111206587:TATA:T	acceptor_loss	1.0000
6:111206588:ATAGA:A	acceptor_loss	1.0000
6:111206589:TAG:T	acceptor_loss	1.0000
6:111206590:A:AG	acceptor_gain	1.0000
6:111206590:A:G	acceptor_loss	1.0000
6:111206591:G:GA	acceptor_gain	1.0000
6:111206591:GAT:G	acceptor_gain	1.0000
6:111206733:CAG:C	donor_loss	1.0000
6:111206735:GGTA:G	donor_loss	1.0000
6:111206737:T:A	donor_loss	1.0000
6:111088094:AGGTG:A	donor_loss	0.9900
6:111088095:GGTGA:G	donor_loss	0.9900
6:111088096:G:T	donor_loss	0.9900
6:111088097:T:G	donor_loss	0.9900
6:111137636:G:GT	donor_gain	0.9900
6:111152821:GAC:G	donor_gain	0.9900
6:111166207:T:A	acceptor_gain	0.9900
6:111172694:GC:G	acceptor_gain	0.9900
6:111172694:GCA:G	acceptor_gain	0.9900
6:111172694:GCAT:G	acceptor_gain	0.9900
6:111205729:G:GT	donor_gain	0.9900
6:111205748:C:G	donor_gain	0.9900

AlphaMissense

3371 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:111177306:T:C	F195L	1.000
6:111177308:C:A	F195L	1.000
6:111177308:C:G	F195L	1.000
6:111177609:T:A	W296R	1.000
6:111177609:T:C	W296R	1.000
6:111218917:G:A	G397E	1.000
6:111218989:G:A	G421E	1.000
6:111087997:G:A	G82E	0.999
6:111172718:G:A	G123R	0.999
6:111172718:G:C	G123R	0.999
6:111172736:T:C	C129R	0.999
6:111172748:A:C	S133R	0.999
6:111172750:C:A	S133R	0.999
6:111172750:C:G	S133R	0.999
6:111172794:G:A	G148D	0.999
6:111172826:A:C	S159R	0.999
6:111172828:T:A	S159R	0.999
6:111172828:T:G	S159R	0.999
6:111177280:C:A	P186H	0.999
6:111177280:C:G	P186R	0.999
6:111177306:T:A	F195I	0.999
6:111177307:T:C	F195S	0.999
6:111177351:A:C	S210R	0.999
6:111177353:C:A	S210R	0.999
6:111177353:C:G	S210R	0.999
6:111177354:A:C	S211R	0.999
6:111177356:T:A	S211R	0.999
6:111177356:T:G	S211R	0.999
6:111177640:G:A	G306E	0.999
6:111218835:G:C	G370R	0.999

dbSNP variants (sampled 300 via entrez): RS1000044223 (6:111189289 C>T), RS1000054502 (6:111104498 A>C,G), RS1000063743 (6:111131579 G>A,T), RS1000110723 (6:111185352 C>G,T), RS1000130359 (6:111097511 G>A), RS1000188881 (6:111104113 T>C), RS1000198163 (6:111196078 G>A), RS1000238793 (6:111093593 A>G), RS1000245007 (6:111136784 A>C,G), RS1000327546 (6:111144096 G>A), RS1000359960 (6:111156305 T>C,G), RS1000402114 (6:111097725 T>C), RS1000413488 (6:111226479 A>C), RS1000425930 (6:111118345 C>A,T), RS1000430266 (6:111150951 C>T)

Disease associations

OMIM: gene MIM:607550 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

18 associations (top):

Study	Trait	p-value
GCST001217_10	Metabolic traits	1.000000e-12
GCST001391_11	Metabolite levels	4.000000e-15
GCST004131_98	Inflammatory bowel disease	4.000000e-10
GCST004133_60	Ulcerative colitis	6.000000e-10
GCST004602_117	Mean corpuscular volume	3.000000e-12
GCST004630_98	Mean corpuscular hemoglobin	5.000000e-11
GCST008097_24	Bisphosphonate-associated atypical femoral fracture	2.000000e-06
GCST008867_1	Tyrosine levels	1.000000e-07
GCST009391_1979	Metabolite levels	1.000000e-08
GCST009391_738	Metabolite levels	4.000000e-06
GCST010002_332	Refractive error	3.000000e-10
GCST012020_124	Serum metabolite levels	7.000000e-11
GCST90002390_446	Mean corpuscular hemoglobin	2.000000e-09
GCST90002390_447	Mean corpuscular hemoglobin	2.000000e-30
GCST90002392_692	Mean corpuscular volume	4.000000e-34
GCST90002392_693	Mean corpuscular volume	1.000000e-09
GCST90002396_334	Mean reticulocyte volume	3.000000e-30
GCST90002397_475	Mean spheric corpuscular volume	4.000000e-26

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004725	metabolite measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0009958	response to bisphosphonate
EFO:0009960	atypical femoral fracture
EFO:0005058	tyrosine measurement
EFO:0010701	mean reticulocyte volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC16 family of monocarboxylate transporters

CTD chemical–gene interactions

47 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, affects cotreatment, increases expression	7
Aflatoxin B1	increases methylation, affects expression, decreases expression	3
nickel sulfate	increases expression	2
Copper	affects binding, decreases expression	2
Estradiol	increases expression, decreases expression	2
Tetrachlorodibenzodioxin	increases expression	2
Tretinoin	decreases expression, increases expression	2
Cyclosporine	decreases expression	2
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
propionaldehyde	increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
terbufos	increases methylation	1
trichostatin A	decreases expression, increases expression	1
beta-lapachone	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
pentabromodiphenyl ether	decreases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
NSC 689534	affects binding, decreases expression	1
(+)-JQ1 compound	increases expression	1
Sunitinib	increases expression	1
Zoledronic Acid	increases expression	1
Vorinostat	increases expression	1
Azathioprine	decreases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4HZ	HCT116-SLC16A10-KO-c3	Cancer cell line	Male
CVCL_D4I0	HCT116-SLC16A10-KO-c5	Cancer cell line	Male
CVCL_TL63	HAP1 SLC16A10 (-) 1	Cancer cell line	Male
CVCL_TL64	HAP1 SLC16A10 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.